{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T18:04:01Z","timestamp":1770401041636,"version":"3.49.0"},"reference-count":58,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15463","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T13:23:46Z","timestamp":1768569826000},"source":"Crossref","is-referenced-by-count":0,"title":["Endostar combined with docetaxel or cisplatin in the management of malignant ascites through hyperthermic intraperitoneal chemotherapy: A retrospective cohort study"],"prefix":"10.3892","volume":"31","author":[{"given":"Jing","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Oncology, Zhejiang Hospital, Hangzhou, Zhejiang 310030, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dashan","family":"Yin","sequence":"additional","affiliation":[{"name":"School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Qian","sequence":"additional","affiliation":[{"name":"The Second School of Clinical Medical, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Zhou","sequence":"additional","affiliation":[{"name":"The Second School of Clinical Medical, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yajun","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine Pharmacy, Zhejiang Hospital, Hangzhou, Zhejiang 310030, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganlu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Zhejiang Hospital, Hangzhou, Zhejiang 310030, P.R. China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"key":"key20260206093156_b1-ol-31-3-15463","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znab117.017","article-title":"O17: Hyaluronic acid dependent adhesion in colorectal cancer peritoneal metastasis","volume":"108","author":"Soliman","year":"2021","journal-title":"Br J Surg"},{"key":"key20260206093156_b2-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1186\/s12885-020-07339-6","article-title":"Prophylactic chemotherapeutic hyperthermic intraperitoneal perfusion reduces peritoneal metastasis in gastric cancer: A retrospective clinical study","volume":"20","author":"Zhu","year":"2020","journal-title":"BMC Cancer"},{"key":"key20260206093156_b3-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/02656736.2019.1579372","article-title":"Intraperitoneal perfusion chemotherapy and whole abdominal hyperthermia using external radiofrequency following radical D2 resection for treatment of advanced gastric cancer","volume":"36","author":"Zhu","year":"2019","journal-title":"Int J Hyperthermia"},{"key":"key20260206093156_b4-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12935-023-02854-5","article-title":"Tumor microenvironment in ovarian cancer peritoneal metastasis","volume":"23","author":"Mei","year":"2023","journal-title":"Cancer Cell Int"},{"key":"key20260206093156_b5-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s10555-020-09924-4","article-title":"Molecular mediators of peritoneal metastasis in pancreatic cancer","volume":"39","author":"Avula","year":"2020","journal-title":"Cancer Metastasis Rev"},{"key":"key20260206093156_b6-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3390\/cancers14010060","article-title":"Peritoneal metastasis: Current status and treatment options","volume":"14","author":"Roth","year":"2021","journal-title":"Cancers (Basel)"},{"key":"key20260206093156_b7-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"6966","DOI":"10.1158\/1078-0432.CCR-05-0910","article-title":"Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model","volume":"11","author":"Hu","year":"2005","journal-title":"Clin Cancer Res"},{"key":"key20260206093156_b8-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3892\/or.2021.7974","article-title":"Direct and indirect anticancer effects of hyperthermic intraperitoneal chemotherapy on peritoneal malignancies (Review)","volume":"45","author":"Zhang","year":"2021","journal-title":"Oncol Rep"},{"key":"key20260206093156_b9-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"1498529","DOI":"10.3389\/fsurg.2024.1498529","article-title":"Challenges following CRS and HIPEC surgery in cancer patients with peritoneal metastasis: A comprehensive review of clinical outcomes","volume":"11","author":"Karimi","year":"2024","journal-title":"Front Surg"},{"key":"key20260206093156_b10-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"433","DOI":"10.2307\/3575883","article-title":"Interaction of thermotolerance and thermosensitization induced in CHO cells by combined hyperthermic treatments at 40 and 43 degrees C","volume":"91","author":"Jung","year":"1982","journal-title":"Radiat Res"},{"key":"key20260206093156_b11-ol-31-3-15463","first-page":"256","article-title":"Clinical delivery system for intraperitoneal hyperthermic chemotherapy","volume":"40","author":"Spratt","year":"1980","journal-title":"Cancer Res"},{"key":"key20260206093156_b12-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1055\/s-0040-1713742","article-title":"Expanding uses of hipec for locally advanced colorectal cancer: A European perspective","volume":"33","author":"Cortes-Guiral","year":"2020","journal-title":"Clin Colon Rectal Surg"},{"key":"key20260206093156_b13-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.critrevonc.2015.04.004","article-title":"Selection of chemotherapy for hyperthermic intraperitoneal use in gastric cancer","volume":"95","author":"Braam","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20260206093156_b14-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1080\/14656566.2020.1766024","article-title":"An overview and update of hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"21","author":"de Bree","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"key20260206093156_b15-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"595","DOI":"10.4149\/neo_2020_190716N640","article-title":"Endostar blocks the metastasis, invasion and angiogenesis of ovarian cancer cells","volume":"67","author":"Ding","year":"2020","journal-title":"Neoplasma"},{"key":"key20260206093156_b16-ol-31-3-15463","first-page":"5412","article-title":"Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis","volume":"59","author":"Shaheen","year":"1999","journal-title":"Cancer Res"},{"key":"key20260206093156_b17-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"e32207","DOI":"10.1097\/MD.0000000000032207","article-title":"Efficacy and safety of endostar combined with cisplatin in treatment of non-small cell lung cancer with malignant pleural effusion: A meta-analysis","volume":"101","author":"Hu","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"key20260206093156_b18-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1186\/s12885-016-2935-4","article-title":"Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: A systematic evaluation and meta-analysis","volume":"16","author":"Biaoxue","year":"2016","journal-title":"BMC Cancer"},{"key":"key20260206093156_b19-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40265-022-01828-7","article-title":"Intraperitoneal chemotherapy for unresectable peritoneal surface malignancies","volume":"83","author":"Guchelaar","year":"2023","journal-title":"Drugs"},{"key":"key20260206093156_b20-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.3390\/cancers15174314","article-title":"Effects of hyperthermia and hyperthermic intraperitoneal chemoperfusion on the peritoneal and tumor immune contexture","volume":"15","author":"Chia","year":"2023","journal-title":"Cancers (Basel)"},{"key":"key20260206093156_b21-ol-31-3-15463","first-page":"849","article-title":"Expert consensus on the clinical application of recombinant human endostatin for the treatment of malignant serous effusions","volume":"25","author":"Chinese Society of Clinical Oncology Antitumor Drug Safety Management Expert Committee and Chinese Society of Clinical Oncology Vascular Targeted Therapy Expert Committee","year":"2020","journal-title":"Chinese Clinical Oncology"},{"key":"key20260206093156_b22-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1759\u20137714.2012.00111.x","article-title":"Low-dose endostatin normalizes the structure and function of tumor vasculature and improves the delivery and anti-tumor efficacy of cytotoxic drugs in a lung cancer xenograft murine model","volume":"3","author":"Ning","year":"2012","journal-title":"Thorac Cancer"},{"key":"key20260206093156_b23-ol-31-3-15463","first-page":"500","article-title":"Clinical observation of recombinant human vascular endostatin durative transfusion combined with window period arterial infusion chemotherapy in the treatment of advanced lung squamous carcinoma","volume":"18","author":"Lv","year":"2015","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"key20260206093156_b24-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S1535-6108(04)00340-X","article-title":"Antiangiogenic therapy: Creating a unique \u2018window\u2019 of opportunity","volume":"6","author":"Lin","year":"2004","journal-title":"Cancer Cell"},{"key":"key20260206093156_b25-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s12094-012-0821-3","article-title":"Clinical study on the recombinant human endostatin regarding improving the blood perfusion and hypoxia of non-small-cell lung cancer","volume":"14","author":"Jiang","year":"2012","journal-title":"Clin Transl Oncol"},{"key":"key20260206093156_b26-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"key20260206093156_b27-ol-31-3-15463","first-page":"191","article-title":"The clinical evaluation of chemotherapeutic agents in cancer","volume-title":"Evaluation of Chemotherapeutic Agents","author":"Karnofsky","year":"1949"},{"key":"key20260206093156_b28-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1200\/JCO.1984.2.3.187","article-title":"Karnofsky performance status revisited: Reliability, validity, and guidelines","volume":"2","author":"Schag","year":"1984","journal-title":"J Clin Oncol"},{"key":"key20260206093156_b29-ol-31-3-15463","article-title":"Common Terminology Criteria for Adverse Events (CTCAE)","year":"2009","journal-title":"Version 4.0"},{"key":"key20260206093156_b30-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ygyno.2011.05.004","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: Multi-institutional phase-II trial","volume":"122","author":"Deraco","year":"2011","journal-title":"Gynecol Oncol"},{"key":"key20260206093156_b31-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-021-02077-6","article-title":"Clinical practice guideline for the treatment of malignant ascites: Section summary in clinical practice guideline for peritoneal dissemination (2021)","volume":"27","author":"Matsusaki","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"key20260206093156_b32-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1158\/1078-0432.CCR-16-0387","article-title":"Expression of vascular endothelial growth factor in ovarian cancer inhibits tumor immunity through the accumulation of myeloid-derived suppressor cells","volume":"23","author":"Horikawa","year":"2017","journal-title":"Clin Cancer Res"},{"key":"key20260206093156_b33-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"3719","DOI":"10.1007\/s13277-015-4198-0","article-title":"The clinical significance of vascular endothelial growth factor in malignant ascites","volume":"37","author":"Zhan","year":"2016","journal-title":"Tumour Biol"},{"key":"key20260206093156_b34-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ygyno.2014.11.072","article-title":"A critical appraisal of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of advanced and recurrent ovarian cancer","volume":"136","author":"Chiva","year":"2015","journal-title":"Gynecol Oncol"},{"key":"key20260206093156_b35-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s12013-014-9965-9","article-title":"Effects of intracavitary administration of Endostar combined with cisplatin in malignant pleural effusion and ascites","volume":"70","author":"Zhao","year":"2014","journal-title":"Cell Biochem Biophys"},{"key":"key20260206093156_b36-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.3892\/ol.2015.3134","article-title":"Endostar inhibits ascites formation and prolongs survival in mouse models of malignant ascites","volume":"9","author":"Wei","year":"2015","journal-title":"Oncol Lett"},{"key":"key20260206093156_b37-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1080\/02656736.2020.1795277","article-title":"Sodium thiosulfate protects from renal impairement following hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin","volume":"37","author":"Laplace","year":"2020","journal-title":"Int J Hyperthermia"},{"key":"key20260206093156_b38-ol-31-3-15463","first-page":"45","article-title":"Chemotherapy for intraperitoneal use: A review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy","volume":"7","author":"Goodman","year":"2016","journal-title":"J Gastrointest Oncol"},{"key":"key20260206093156_b39-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"9688","DOI":"10.1007\/s12274-023-5541-1","article-title":"Microwave triggered multifunctional nanoplatform for targeted photothermal-chemotherapy in castration-resistant prostate cancer","volume":"16","author":"Liu","year":"2023","journal-title":"Nano Res"},{"key":"key20260206093156_b40-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.canlet.2018.04.030","article-title":"Inhibition of MAPKAPK2\/ MK2 facilitates DNA replication upon cancer cell treatment with gemcitabine but not cisplatin","volume":"428","author":"Li","year":"2018","journal-title":"Cancer Lett"},{"key":"key20260206093156_b41-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/kjm2.12766","article-title":"EGFR-mediated hyperacetylation of tubulin induced docetaxel resistance by downregulation of HDAC6 and upregulation of MCAK and PLK1 in prostate cancer cells","volume":"40","author":"Pu","year":"2024","journal-title":"Kaohsiung J Med Sci"},{"key":"key20260206093156_b42-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"Van Driel","year":"2018","journal-title":"N Engl J Med"},{"key":"key20260206093156_b43-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.2217\/fon-2021-0896","article-title":"Intraperitoneal Infusion of Recombinant Human Endostatin Improves Prognosis in Gastric Cancer Ascites","volume":"18","author":"Zhan","year":"2022","journal-title":"Future Oncol"},{"key":"key20260206093156_b44-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"2467296","DOI":"10.1080\/02656736.2025.2467296","article-title":"Cisplatin + docetaxel improves survival over cisplatin + mitomycin C in hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei: A retrospective study based on propensity score matching","volume":"42","author":"Fu","year":"2025","journal-title":"Int J Hyperthermia"},{"key":"key20260206093156_b45-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1245\/s10434-025-17000-w","article-title":"Dynamic assessment of local abdominal tissue concentrations of cisplatin during a HIPEC procedure: Insights from a porcine model","volume":"32","author":"Harlev","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"key20260206093156_b46-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s12885-023-11665-w","article-title":"Multi-omics sequencing revealed endostar combined with cisplatin treated non small cell lung cancer via anti-angiogenesis","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Cancer"},{"key":"key20260206093156_b47-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.3109\/0886022X.2014.949758","article-title":"The incidence of cisplatin nephrotoxicity post hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery","volume":"36","author":"Hakeam","year":"2014","journal-title":"Ren Fail"},{"key":"key20260206093156_b48-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1007\/s00423-021-02279-6","article-title":"Acute renal disease in patients with ovarian peritoneal carcinomatosis treated with cytoreduction and HIPEC: The influence of surgery and the cytostatic agent used","volume":"406","author":"G\u00f3mez-Ruiz","year":"2021","journal-title":"Langenbecks Arch Surg"},{"key":"key20260206093156_b49-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.suronc.2018.05.025","article-title":"Nephrotoxicity and long-term survival investigations for patients with peritoneal carcinomatosis using hyperthermic intraperitoneal chemotherapy with cisplatin: A retrospective cohort study","volume":"27","author":"Ye","year":"2018","journal-title":"Surg Oncol"},{"key":"key20260206093156_b50-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1080\/02656736.2017.1293304","article-title":"Acute kidney injury in ovarian cancer patients undergoing cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy","volume":"33","author":"Sin","year":"2017","journal-title":"Int J Hyperthermia"},{"key":"key20260206093156_b51-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ejso.2020.07.037","article-title":"Systemic exposure of oxaliplatin and docetaxel in gastric cancer patients with peritonitis carcinomatosis treated with intraperitoneal hyperthermic chemotherapy","volume":"47","author":"Koemans","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"key20260206093156_b52-ol-31-3-15463","first-page":"5896","article-title":"Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: Dose-limiting toxicity and pharmacokinetics","volume":"9","author":"Morgan","year":"2003","journal-title":"Clin Cancer Res"},{"key":"key20260206093156_b53-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s00280-002-0439-1","article-title":"Docetaxel: Pharmacokinetics and tissue levels after intraperitoneal and intravenous administration in a rat model","volume":"49","author":"Marchettini","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20260206093156_b54-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.3390\/toxins2112490","article-title":"Mechanisms of cisplatin nephrotoxicity","volume":"2","author":"Miller","year":"2010","journal-title":"Toxins (Basel)"},{"key":"key20260206093156_b55-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/00003088-199936020-00002","article-title":"Clinical pharmacokinetics of docetaxel","volume":"36","author":"Clarke","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"key20260206093156_b56-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s10120-020-01112-1","article-title":"Docetaxel plus S-1 versus cisplatin plus S-1 in unresectable gastric cancer without measurable lesions: A randomized phase II trial (HERBIS-3)","volume":"24","author":"Kurokawa","year":"2021","journal-title":"Gastric Cancer"},{"key":"key20260206093156_b57-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4103\/sjmms.sjmms_767_24","article-title":"Exploratory and confirmatory factor analysis of the arabic medical outcomes study-social support Survey-6 among Saudi adults","volume":"13","author":"Alyami","year":"2025","journal-title":"Saudi J Med Med Sci"},{"key":"key20260206093156_b58-ol-31-3-15463","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1192\/bjp.128.3.280","article-title":"The SCL-90 and the MMPI: A step in the validation of a new self-report scale","volume":"128","author":"Derogatis","year":"1976","journal-title":"Br J Psychiatry"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T07:32:05Z","timestamp":1770363125000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":58,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,1,15]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15463","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"article-number":"111"}}